BFRI Profile
Biofrontera Inc., a pioneering biopharmaceutical firm, specializes in the commercialization of innovative pharmaceutical products tailored for dermatological conditions across the United States. Central to its product portfolio is Ameluz, a prescription drug renowned for its efficacy in photodynamic therapy. This therapy utilizes Biofrontera's proprietary RhodoLED lamp series to treat actinic keratosis, addressing both lesion-directed and field-directed treatments on sensitive areas such as the face and scalp.
In addition to its flagship product, Ameluz, Biofrontera Inc. offers Xepi, a prescription cream specifically formulated for the treatment of impetigo, further demonstrating the company's commitment to advancing therapeutic options for dermatological disorders. Leveraging decades of scientific research and clinical expertise, Biofrontera Inc. continues to innovate in the field of dermatology, developing treatments that improve patient outcomes and enhance quality of life.
Founded in 1997 and headquartered in Woburn, Massachusetts, Biofrontera Inc. has established itself as a trailblazer in dermatological healthcare. The company's roots in scientific innovation and patient-centered care underscore its mission to address unmet medical needs and deliver effective solutions to healthcare providers and patients alike. With a dedicated focus on research and development, Biofrontera Inc. remains at the forefront of dermatological innovation, driving advancements in treatment modalities and therapeutic outcomes.
Situated in Woburn, Massachusetts, a strategic location within the biotechnology corridor of the United States, Biofrontera Inc. benefits from proximity to leading research institutions and a vibrant ecosystem of healthcare innovation. This advantageous setting facilitates collaboration with industry experts and accelerates the translation of scientific discoveries into clinically meaningful treatments. Biofrontera Inc.'s strategic initiatives and commitment to excellence position it as a trusted partner in dermatological healthcare, poised for continued growth and impact in the global pharmaceutical market.
|
